Article
Gilead lifted by fast sales of COVID-19 drug Veklury. Will they last?
Rating:
0.0
Views:
283
Likes:
1
Library:
1
Veklury, which was approved by the FDA last week, earned Gilead nearly $900 million in the third quarter, although U.S. sales could slow in the months ahead.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value